Hummingbird Diagnostics to Present Poster on miLung Small RNA-Based Blood Test at the ASCO 2023 Annual Meeting


More Information



HEIDELBERG, Germany, May 31, 2023 – Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.

Details of the poster presentation are as follows:


Title: Early detection of lung cancer using small RNAs

Presenting Author: Bruno Steinkraus, PhD, Chief Scientific Officer of Hummingbird Diagnostics

Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Abstract: #3035
Poster Board: #233
Location: Hall A
Date/Time: June 3, 2023 from 8:00 AM – 11:00 AM CDT


About Hummingbird Diagnostics GmbH

Hummingbird is harnessing the predictive power of blood-borne miRNAs to provide insights into human health and disease. Analyzing miRNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies.


Media contact:

MacDougall Advisors

Karen Sharma